Comparison of 0.5% Levobupivacaine with Dexmedetomidine and 0.5% Plain Levobupivacaine for Supraclavicular brachial plexus Block

Comparison of 0.5% levobupivacaine with dexmedetomidine versus plain 0.5% levobupivacaine in ultrasound guided supraclavicular brachial plexus block for upper limb surgeries- A randomised control double blinded study - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087363

Enrollment

Registered

2025-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S520- Fracture of upper end of ulna Health Condition 2: S621- Fracture of other and unspecifiedcarpal bone(s) Health Condition 3: S521- Fracture of upper end of radius Health Condition 4: S523- Fracture of shaft of radius Health Condition 5: S629- Unspecified fracture of wrist andhand Health Condition 6: S522- Fracture of shaft of ulna Health Condition 7: O- Medical and Surgical

Interventions

Intervention1: Levobupivacaine: Patients will receive USG guided supraclavicular block using 29ml 0.5% levobupivacine and 1ml normal saline. Total duration of study is 1.5 years Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: 1- Patient giving consent for surgery 2- Age between 35-65 years 3- Weight 50-70 kg 4- ASA grade 1 & 2 5- Patients undergoing elective upper limb surgeries 6- All lab investigations within normal range

Exclusion criteria

Exclusion criteria: 1.Patients belonging to ASA grade III, IV or V & emergency cases. 2.Patients with known hypersensitivity or contra-indications to study drugs. 3.Patients on anti coagulants or with bleeding disorders. 4.Local infection at injection site. 5.Patients having cardio respiratory dysfunction or renal, hepatic or metabolic derangements or history of epilepsy 6.Neurological deficits involving the brachial plexus. 7.Those on sedative or antipsychotics. 8.Body mass index (BMI)more than 35 9.Patients on other vasodilator or negative chronotropic agents. 10.Patients have altered sensorium

Design outcomes

Primary

Measure	Time frame
To find out the duration of analgesiaTimepoint: Every 5 minutes for 30 minutes	—

Secondary

Measure	Time frame
1. Effect of sensory and motor characteristics like onset and duration. 2. Complications and side effects, if any.Timepoint: Every 5 minutes for 30 minutes	—

Countries

India

Contacts

Public ContactDr Sonali Beniwal

Jhalawar Medical college

drsonalisms@gmail.com9214540552

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026